Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LYRANASDAQ:NXLNASDAQ:OSRHNASDAQ:SINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLYRALyra Therapeutics$11.41-3.8%$7.63$3.81▼$37.50$15.11M-0.01377,860 shs184,472 shsNXLNexalin Technology$1.13-6.9%$1.45$0.59▼$4.49$19.43M4199,963 shs85,107 shsOSRHOSR$1.41-13.8%$1.34$1.02▼$13.40$27.08M1.612.67 million shs91,304 shsSINTSintx Technologies$3.29+6.9%$2.56$1.71▼$8.60$8.27M0.73937,052 shs96,703 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLYRALyra Therapeutics-12.22%-53.22%+151.06%+37.79%-23.55%NXLNexalin Technology-0.41%+2.10%+2.10%-43.49%+94.52%OSRHOSR+1.24%+16.43%+34.71%+13.59%+162,999,900.00%SINTSintx Technologies+6.57%+10.39%-6.95%-9.94%-35.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLYRALyra Therapeutics3.0592 of 5 stars3.24.00.00.03.91.70.6NXLNexalin Technology2.3741 of 5 stars3.53.00.00.02.71.70.0OSRHOSRN/AN/AN/AN/AN/AN/AN/AN/ASINTSintx Technologies2.1975 of 5 stars3.52.00.00.01.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLYRALyra Therapeutics 2.33Hold$100.00776.81% UpsideNXLNexalin Technology 3.00Buy$5.00342.09% UpsideOSRHOSR 0.00N/AN/AN/ASINTSintx Technologies 3.00Buy$28.00750.03% UpsideCurrent Analyst Ratings BreakdownLatest SINT, OSRH, LYRA, and NXL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025SINTSintx TechnologiesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $28.004/21/2025SINTSintx TechnologiesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$70.00 ➝ $30.003/24/2025NXLNexalin TechnologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$5.003/14/2025LYRALyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$100.00 ➝ $100.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLYRALyra Therapeutics$1.19M12.75N/AN/A$1.56 per share7.31NXLNexalin Technology$131.07K148.23N/AN/A$0.43 per share2.63OSRHOSR-$148.95K-181.83N/AN/AN/A∞SINTSintx Technologies$1.23M6.73N/AN/A$329.74 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLYRALyra Therapeutics-$62.68M-$60.50N/AN/AN/A-6,635.76%-125.07%-59.74%8/12/2025 (Estimated)NXLNexalin Technology-$4.65M-$0.83N/A∞N/A-3,407.98%-187.59%-167.21%N/AOSRHOSRN/AN/A0.00∞N/AN/AN/AN/AN/ASINTSintx Technologies-$8.26M-$50.56N/A∞N/A-358.79%-140.68%-78.29%8/4/2025 (Estimated)Latest SINT, OSRH, LYRA, and NXL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025OSRHOSRN/A-$1.04N/A-$1.04N/A$0.76 million5/15/2025Q1 2025SINTSintx Technologies-$0.71-$1.29-$0.58-$1.29$0.73 million$0.37 million5/13/2025Q1 2025NXLNexalin Technology-$0.10-$0.15-$0.05-$0.15$0.04 million$0.04 million5/6/2025Q1 2025LYRALyra Therapeutics-$7.50-$6.00+$1.50-$0.13$0.16 million$0.18 million3/14/2025Q4 2024NXLNexalin TechnologyN/A-$0.28N/A-$0.28N/A$0.03 million3/13/2025Q4 2024LYRALyra Therapeutics-$6.00-$8.00-$2.00-$0.16$0.21 million$0.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLYRALyra TherapeuticsN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLYRALyra TherapeuticsN/A3.643.64NXLNexalin TechnologyN/A16.4215.89OSRHOSRN/AN/AN/ASINTSintx TechnologiesN/A3.042.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLYRALyra Therapeutics95.62%NXLNexalin Technology0.65%OSRHOSR55.30%SINTSintx Technologies18.38%Insider OwnershipCompanyInsider OwnershipLYRALyra Therapeutics3.25%NXLNexalin Technology24.00%OSRHOSR33.67%SINTSintx Technologies0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLYRALyra Therapeutics501.33 million62.39 millionOptionableNXLNexalin Technology317.18 million10.11 millionNot OptionableOSRHOSRN/A19.28 million2.68 millionN/ASINTSintx Technologies402.51 million1.34 millionNot OptionableSINT, OSRH, LYRA, and NXL HeadlinesRecent News About These CompaniesSINTX Technologies Announces Strategic Vision Focused on Expansion Across Key SectorsJune 13 at 5:10 AM | tmcnet.comSintx Technologies Draws Heavy Retail Buzz On New Patent Push, SubsidiaryMay 23, 2025 | msn.comSINTX Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech MarketMay 22, 2025 | globenewswire.comSiNtx Technologies Inc.May 19, 2025 | marketwatch.comSiNtx Technologies Inc.May 19, 2025 | marketwatch.comSINTX Technologies, Inc.: SINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device CommercializationMay 16, 2025 | finanznachrichten.deMark Lewis Anderson Purchases 5,000 Shares of Sintx Technologies, Inc. (NASDAQ:SINT) StockMay 15, 2025 | insidertrades.comSINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device CommercializationMay 15, 2025 | globenewswire.comSintx Technologies, Inc. (NASDAQ:SINT) Insider Gregg R. Honigblum Buys 10,000 SharesMay 1, 2025 | insidertrades.comSintx Technologies Appoints Five New Board DirectorsApril 8, 2025 | tipranks.comSintx Technologies announces changes to board, Chairman Bal to retireApril 5, 2025 | markets.businessinsider.comSINTX Technologies Announces Strategic Changes to Board of DirectorsApril 3, 2025 | markets.businessinsider.comSINTX: Peer-reviewed Study Shows Biomechanical Advantages Of Silicon Nitride In ACDF ProceduresMarch 21, 2025 | nasdaq.comMaxim Group Reaffirms Their Hold Rating on Sintx Technologies (SINT)March 21, 2025 | markets.businessinsider.comSintx Technologies announces publication of study on silicon nitride in ACDFMarch 20, 2025 | markets.businessinsider.comSintx Technologies files to sell 3.01M shares of common stock for holdersMarch 20, 2025 | markets.businessinsider.comSINTX Technologies Announces Publication of Study Confirming Superior Performance of Silicon Nitride in Cervical Spine FusionMarch 19, 2025 | markets.businessinsider.comSintx Technologies Announces Board Chairman TransitionMarch 17, 2025 | markets.businessinsider.com3SINT : Why SINTX Technologies Stock Is Down 21%February 26, 2025 | benzinga.comSintx Technologies prices 1.45M shares at $3.45 in private placementFebruary 26, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSINT, OSRH, LYRA, and NXL Company DescriptionsLyra Therapeutics NASDAQ:LYRA$11.40 -0.45 (-3.76%) As of 02:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Nexalin Technology NASDAQ:NXL$1.13 -0.08 (-6.91%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.OSR NASDAQ:OSRH$1.40 -0.23 (-13.80%) As of 02:20 PM EasternOSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.Sintx Technologies NASDAQ:SINT$3.29 +0.21 (+6.95%) As of 02:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: Two Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
